Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.5
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Announces Support of Final Rule From FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Atos Cuts Outlook on Softer Market as Clients Await Outcome of Rescue Plan -- Update
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Express News | Atossa Therapeutics: Data From Study Anticipated in 2026
Express News | Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-Spy 2 Trial Combining (Z)-Endoxifen With Abemaciclib for Er+/Her2- Breast Cancer
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen With Abemaciclib for ER+/HER2- Breast Cancer
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Jason McCarthy maintains $Atossa Therapeutics(ATOS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 21.6%
Atossa Therapeutics: A Promising Buy in Oncology With Strong Financials and Upcoming Trial Milestones
Atossa Therapeutics GAAP EPS of -$0.05 In-line
Atossa Therapeutics: A Promising Buy Amid Anticipated Clinical Breakthroughs
Atossa Therapeutics | 10-Q: Q2 2024 Earnings Report
Atossa Therapeutics Ended 2Q With $79.5 M in Cash and Cash Equivalents and No Debt >ATOS
Express News | Atossa Therapeutics Q2 Operating Expenses USD 7.105 Million
Express News | Atossa Therapeutics Q2 Pretax Profit USD -6.049 Million